# A Study to Assess Pharmacokinetics (PK) of Preladenant in Participants With Chronic Renal Impairment (CRI) (P06512)

> **NCT01323855** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 46 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** Preladenant

## Key facts

- **NCT ID:** NCT01323855
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03-28
- **Primary completion:** 2011-11-29
- **Final completion:** 2011-11-29
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2018-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01323855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01323855, "A Study to Assess Pharmacokinetics (PK) of Preladenant in Participants With Chronic Renal Impairment (CRI) (P06512)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01323855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*